Insmed

INSM | NASDAQ

Price Alert Chart Builder DCF Calculator

$120.02

-$0.98 (-0.81%)

Sep 22, 2026, 11:48 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.81%

(1D)

Rating

Updated: Sep 11, 2026

37.4

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $26.01B

1D Range

119.80 121.66

52W Range

90.39 212.75

Valuation (TTM)

PE -29.44

PB 34.62

EV/EBITDA -32.60

Valuation (NTM)

Forward PE 138.00

Forward PEG 0.19

Price Target $196.93

Cash Flow

FCF Yield -4.1%

SBC Adj. FCF Yield -4.7%

SBC Impact -15.4%

Margins

Gross Margin 83.3%

Operating Margin -71.9%

FCF Margin -93.5%

Growth (CAGR)

Revenue 3Y | 5Y 61.6% | 46.1%

Dil EPS 3Y | 5Y 12.6% | -3.5%

FCF 3Y | 5Y -28.1% | -26.3%

Returns

ROA -41.6%

ROE -111.3%

ROIC -48.9%

Financial Health

Net Cash

$1.12B

Current Ratio 3.72

Interest Coverage -10.05

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's markete...

Sector Healthcare

Industry Biotechnology

Employees 1,664

IPO Date May 31, 2000

Website www.insmed.com

Fiscal Year January - December

Full Company Profile

Latest News

5 hours ago · seekingalpha.com

Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case

Insmed is rated Buy, driven by Brinsupri's blockbuster launch and strong TPIP Phase 2b data. Brinsupri generated $517m in 1H 2026, faces minimal competition, and targets $7bn+ peak sales with COPD/asthma comorbidity upside. TPIP's Phase 2b results exceeded expectations; four Phase 3 indications could yield $6bn+ peak sales if approved.

1 day ago · prnewswire.com

FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

—sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study— —Full Approval Could Bring ARIKAYCE to Patients Earlier in Their Disease Course and Would Fulfill Post-Marketing Requirement From FDA— BRIDGEWATER, N.J., Sept. 21, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Supplemental New Drug Application (sNDA) for review of ARIKAYCE® (amikacin liposome inhalation suspension) for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen.

6 days ago · prnewswire.com

Insmed Expands Community Impact During Fifth Annual Global Day of Good

Company-wide day of service brings together more than 1,350 employees to support over 50 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J., Sept. 16, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today holds its fifth annual Global Day of Good, a company-wide day of service during which employees volunteer simultaneously in their respective communities around the world.

8 days ago · seekingalpha.com

Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

13 days ago · seekingalpha.com

Insmed Incorporated (INSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

14 days ago · seekingalpha.com

Insmed: A Strong Launch And A Much Bigger Peak Sales Opportunity

Insmed is rated Strong Buy with a $175 target, offering ~39% upside from current levels. BRINSUPRI's rapid launch and raised peak sales guidance to $7B+ underpin INSM's commercial momentum and pipeline credibility. Management now estimates combined peak sales of $14B+ for its three lead drugs, up 75%, though some projections are not yet data-backed.

18 days ago · prnewswire.com

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 128 new employees.

27 days ago · prnewswire.com

Insmed to Present at September 2026 Investor Conferences

BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m.

29 days ago · prnewswire.com

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — BRIDGEWATER, N.J., Aug. 24, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved BRINSUPRI ® (brensocatib 25-mg tablet), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older.